U.S. Small Molecule CDMO Market Size, Share, Trend, Industry Analysis Report By Drug Type (Innovators, Generics), By Product, By Application – Market Forecast, 2025–2034
Description
The U.S. small molecule CDMO market size is expected to reach USD 49.82 billion by 2034, according to a new study by Polaris Market Research. The report “U.S. Small Molecule CDMO Market Size, Share, Trend, Industry Analysis Report By Drug Type (Innovators, Generics), By Product, By Application, By Region – Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.
The U.S. small molecule CDMO market encompasses contract development and manufacturing services dedicated to producing small molecule drugs, supporting pharmaceutical companies across the drug lifecycle from early-stage development to commercial manufacturing. The market is driven by a rising shift toward outsourcing to reduce operational costs, accelerate time-to-market, and access specialized capabilities, particularly in complex chemistries and high-potency active pharmaceutical ingredients. Growing demand for targeted therapies, along with the expansion of pipelines in oncology, cardiovascular, and central nervous system disorders, is fueling the need for flexible and scalable manufacturing solutions. Industry trends indicate a strong move toward continuous manufacturing, advanced analytical services, and integration of digital platforms for process optimization and quality assurance. Increasing investments in high-containment facilities and specialized formulation technologies are enhancing the ability to handle niche and high-value products.
Opportunities lie in supporting innovators developing novel therapies, as well as generic manufacturers seeking cost-efficient production solutions amid patent expirations. Expansion into highly regulated and specialized segments such as oncology APIs, low-volume high-potency compounds, and complex oral solid dosage forms offers significant growth potential. Strategic collaborations, technology adoption, and tailored service models are enabling CDMOs to strengthen client relationships and differentiate in a competitive landscape. The convergence of advanced manufacturing approaches, regulatory compliance expertise, and specialized capabilities positions the market for sustained growth as pharmaceutical companies continue to rely on outsourcing partners for both development and commercial supply.
U.S. Small Molecule CDMO Market Report Highlights
By product, the active pharmaceutical ingredient segment dominated the market in 2024 due to the rising complexity of drug formulations and the growing need for specialized manufacturing capabilities.
Based on drug type, the innovators segment held the largest revenue share in 2024 due to a surge in novel small molecule development pipelines, particularly in oncology, neurology, and metabolic disorders.
A few key players in the U.S. small molecule CDMO market include Aurigene Pharmaceutical Services Ltd.; Bellen Chemistry; Cambrex Corporation; Catalent, Inc.; CordenPharma International; Eurofins Scientific; Lonza; Recipharm AB; Siegfried Holding AG; and Thermo Fisher Scientific Inc.
Polaris Market Research has segmented the market report on the basis of product, drug type, and application:
By Product Outlook (Revenue, USD Billion, 2020–2034)
Active Pharmaceutical Ingredients (API)
Finished Drug Products
By Drug Type Outlook (Revenue, USD Billion, 2020–2034)
Innovators
Generics
By Application Outlook (Revenue, USD Billion, 2020–2034)
Oncology
Cardiovascular Disease
Central Nervous System (CNS) Conditions
Autoimmune/Inflammation
Others
The U.S. small molecule CDMO market encompasses contract development and manufacturing services dedicated to producing small molecule drugs, supporting pharmaceutical companies across the drug lifecycle from early-stage development to commercial manufacturing. The market is driven by a rising shift toward outsourcing to reduce operational costs, accelerate time-to-market, and access specialized capabilities, particularly in complex chemistries and high-potency active pharmaceutical ingredients. Growing demand for targeted therapies, along with the expansion of pipelines in oncology, cardiovascular, and central nervous system disorders, is fueling the need for flexible and scalable manufacturing solutions. Industry trends indicate a strong move toward continuous manufacturing, advanced analytical services, and integration of digital platforms for process optimization and quality assurance. Increasing investments in high-containment facilities and specialized formulation technologies are enhancing the ability to handle niche and high-value products.
Opportunities lie in supporting innovators developing novel therapies, as well as generic manufacturers seeking cost-efficient production solutions amid patent expirations. Expansion into highly regulated and specialized segments such as oncology APIs, low-volume high-potency compounds, and complex oral solid dosage forms offers significant growth potential. Strategic collaborations, technology adoption, and tailored service models are enabling CDMOs to strengthen client relationships and differentiate in a competitive landscape. The convergence of advanced manufacturing approaches, regulatory compliance expertise, and specialized capabilities positions the market for sustained growth as pharmaceutical companies continue to rely on outsourcing partners for both development and commercial supply.
U.S. Small Molecule CDMO Market Report Highlights
By product, the active pharmaceutical ingredient segment dominated the market in 2024 due to the rising complexity of drug formulations and the growing need for specialized manufacturing capabilities.
Based on drug type, the innovators segment held the largest revenue share in 2024 due to a surge in novel small molecule development pipelines, particularly in oncology, neurology, and metabolic disorders.
A few key players in the U.S. small molecule CDMO market include Aurigene Pharmaceutical Services Ltd.; Bellen Chemistry; Cambrex Corporation; Catalent, Inc.; CordenPharma International; Eurofins Scientific; Lonza; Recipharm AB; Siegfried Holding AG; and Thermo Fisher Scientific Inc.
Polaris Market Research has segmented the market report on the basis of product, drug type, and application:
By Product Outlook (Revenue, USD Billion, 2020–2034)
Active Pharmaceutical Ingredients (API)
Finished Drug Products
By Drug Type Outlook (Revenue, USD Billion, 2020–2034)
Innovators
Generics
By Application Outlook (Revenue, USD Billion, 2020–2034)
Oncology
Cardiovascular Disease
Central Nervous System (CNS) Conditions
Autoimmune/Inflammation
Others
Table of Contents
125 Pages
- 1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
- 2. Executive Summary
- 2.1. Market Highlights
- 3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
- 4. U.S. Small Molecule CDMO Market Insights
- 4.1. Small Molecule CDMO Market – Market Snapshot
- 4.2. Small Molecule CDMO Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Rising Outsourcing by Pharma Companies
- 4.2.1.2. Expansion of Oncology Drug Development
- 4.2.2. Restraints and Challenges
- 4.2.2.1. High operational costs and talent shortages in specialized chemistry roles limit scalability for mid-sized CDMOs
- 4.3. Porter’s Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. Small Molecule CDMO Market Trends
- 4.6. Value Chain Analysis
- 5. U.S. Small Molecule CDMO Market, by Product
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. U.S. Small Molecule CDMO Market, by Product, 2020-2034 (USD Billion)
- 5.3. Active Pharmaceutical Ingredients (API)
- 5.3.1. U.S. Small Molecule CDMO Market, by Active Pharmaceutical Ingredients (API), 2020-2034 (USD Billion)
- 5.4. Finished Drug Products
- 5.4.1. U.S. Small Molecule CDMO Market, by Finished Drug Products, 2020-2034 (USD Billion)
- 6. U.S. Small Molecule CDMO Market, by Drug Type
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. U.S. Small Molecule CDMO Market, by Drug Type, 2020-2034 (USD Billion)
- 6.3. Innovators
- 6.3.1. U.S. Small Molecule CDMO Market, by Innovators, 2020-2034 (USD Billion)
- 6.4. Generics
- 6.4.1. U.S. Small Molecule CDMO Market, by Generics, 2020-2034 (USD Billion)
- 6.5. Manual
- 6.5.1. U.S. Small Molecule CDMO Market, by Manual, 2020-2034 (USD Billion)
- 7. U.S. Small Molecule CDMO Market, by Application
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. U.S. Small Molecule CDMO Market, by Application, 2020-2034 (USD Billion)
- 7.3. Oncology
- 7.3.1. U.S. Small Molecule CDMO Market, by Oncology, 2020-2034 (USD Billion)
- 7.4. Cardiovascular Disease
- 7.4.1. U.S. Small Molecule CDMO Market, by Cardiovascular Disease, 2020-2034 (USD Billion)
- 7.5. Central Nervous System (CNS) Conditions
- 7.5.1. U.S. Small Molecule CDMO Market, by Central Nervous System (CNS) Conditions, 2020-2034 (USD Billion)
- 7.6. Autoimmune/Inflammation
- 7.6.1. U.S. Small Molecule CDMO Market, by Autoimmune/Inflammation, 2020-2034 (USD Billion)
- 7.7. Others
- 7.7.1. U.S. Small Molecule CDMO Market, by Others, 2020-2034 (USD Billion)
- 8. Competitive Landscape
- 8.1. Expansion and Acquisition Analysis
- 8.1.1. Expansion
- 8.1.2. Acquisitions
- 8.2. Partnerships/Collaborations/Agreements/Exhibitions
- 9. Company Profiles
- 9.1. Aurigene Pharmaceutical Services Ltd.
- 9.1.1. Company Overview
- 9.1.2. Financial Performance
- 9.1.3. Product Benchmarking
- 9.1.4. Recent Development
- 9.2. Bellen Chemistry
- 9.2.1. Company Overview
- 9.2.2. Financial Performance
- 9.2.3. Product Benchmarking
- 9.2.4. Recent Development
- 9.3. Cambrex Corporation
- 9.3.1. Company Overview
- 9.3.2. Financial Performance
- 9.3.3. Product Benchmarking
- 9.3.4. Recent Development
- 9.4. Catalent, Inc.
- 9.4.1. Company Overview
- 9.4.2. Financial Performance
- 9.4.3. Product Benchmarking
- 9.4.4. Recent Development
- 9.5. CordenPharma International
- 9.5.1. Company Overview
- 9.5.2. Financial Performance
- 9.5.3. Product Benchmarking
- 9.5.4. Recent Development
- 9.6. Eurofins Scientific
- 9.6.1. Company Overview
- 9.6.2. Financial Performance
- 9.6.3. Product Benchmarking
- 9.6.4. Recent Development
- 9.7. Lonza
- 9.7.1. Company Overview
- 9.7.2. Financial Performance
- 9.7.3. Product Benchmarking
- 9.7.4. Recent Development
- 9.8. Recipharm AB
- 9.8.1. Company Overview
- 9.8.2. Financial Performance
- 9.8.3. Product Benchmarking
- 9.8.4. Recent Development
- 9.9. Siegfried Holding AG
- 9.9.1. Company Overview
- 9.9.2. Financial Performance
- 9.9.3. Product Benchmarking
- 9.9.4. Recent Development
- 9.10. Thermo Fisher Scientific Inc.
- 9.10.1. Company Overview
- 9.10.2. Financial Performance
- 9.10.3. Product Benchmarking
- 9.10.4. Recent Development
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.